Phase II study of erlotinib for chemotherapy-naïve patients with advanced or metastatic non-small cell lung cancer who are ineligible for platinum doublets

Cancer Chemotherapy and Pharmacology

Volumn 67, Issue 1, 2011, Pages 35-39

  Lee, Dae Ho ^a   Kim, Sang We ^a   Suh, Cheolwon ^a   Han, Yun Hee ^a   Lee, Jung Shin ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Chemotherapy na ve; Erlotinib; Non small cell lung cancer; Platinum doublet

Indexed keywords

CARBOPLATIN; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEMCITABINE; PEMETREXED;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTICLE; ASTHENIA; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG EXPOSURE; DRUG RESPONSE; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; MALE; METASTASIS; MUCOSA INFLAMMATION; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SIDE EFFECT; WILD TYPE;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; ASIAN CONTINENTAL ANCESTRY GROUP; CARCINOMA, NON-SMALL-CELL LUNG; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL; TREATMENT OUTCOME;

EID: 78651108994     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-010-1280-6     Document Type: Article

References (19)

1. DG Pfister DH Johnson CG Azzoli, et al. 2004 American society of clinical oncology treatment of unresectable non-small cell lung cancer guideline: update 2003 J Clin Oncol 22 330 353 10.1200/JCO.2004.09.053 14691125 (Pubitemid 41095099)
2. A Sandler R Gray MC Perry, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small cell lung cancer N Engl J Med 355 2542 2550 1:CAS:528:DC%2BD28XhtlWqsbzI 10.1056/NEJMoa061884 17167137 (Pubitemid 44917502)
3. N Ebi H Semba SJ Tokunaga, et al. 2008 A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer J Thorac Oncol 3 1166 1171 10.1097/JTO. 0b013e318186a88d 18827614
4. L Crino F Cappuzzo P Zatloukal, et al. 2008 Gefitinib versus vinorelbine in chemotherapy-naïve elderly patients with advanced non-small cell lung cancer (INVITE): a randomized, phase II study J Clin Oncol 26 4253 4260 1:CAS:528:DC%2BD1cXhtF2it7bL 10.1200/JCO.2007.15.0672 18779612
5. G Goss D Ferry R Wierzbicki, et al. 2009 Randomized phase II study of gefitinib compared with placebo in chemotherapy-naïve patients with advanced non-small cell lung cancer and poor performance status J Clin Oncol 27 2253 2260 1:CAS:528:DC%2BD1MXlvFOgs7o%3D 10.1200/JCO.2008.18.4408 19289623
6. FA Shepherd JR Rodrigues Pereira T Ciuleanu, et al. 2005 Erlotinib in previously treated non-small cell lung cancer N Engl J Med 353 123 132 1:CAS:528:DC%2BD2MXmtFaksbo%3D 10.1056/NEJMoa050753 16014882 (Pubitemid 41058344)
7. N Thatcher A Chang P Parikh, et al. 2005 Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small cell lung cancer: results from a randomized placebo-controlled, multicenter study (Iressa Survival Evaluation in Lung Cancer) Lancet 366 1527 1537 1:CAS:528: DC%2BD2MXhtFKhsbfP 10.1016/S0140-6736(05)67625-8 16257339 (Pubitemid 41540110)
8. BC Cho CK Im MS Park, et al. 2007 Phase II study of erlotinib in advanced non-small-cell lung cancer after failure of gefitinib J Clin Oncol 25 2528 2533 1:CAS:528:DC%2BD2sXotV2mt7s%3D 10.1200/JCO.2006.10.4166 17577030 (Pubitemid 47041225)
9. DH Lee SW Kim C Suh, et al. 2008 Phase II study of erlotinib as a salvage treatment for non-small-cell lung cancer patients after failure of gefitinib treatment Ann Oncol 19 2039 2042 1:STN:280:DC%2BD1cjlsFentQ%3D%3D 10.1093/annonc/mdn423 18644828
10. R Lilenbaum R Axelrod S Thomas, et al. 2008 Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2 J Clin Oncol 26 863 869 1:CAS:528:DC%2BD1cXjtFelsb0%3D 10.1200/JCO.2007.13.2720 18281658 (Pubitemid 351398077)
11. PJ Hesketh K Chansky AJ Wozniak, et al. 2008 Southwest Oncology Group phase II trial (S0341) of erlotinib (OSI-774) in patients with advanced non-small cell lung cancer and a performance status of 2 J Thorac Oncol 3 1026 1031 10.1097/JTO.0b013e318183aa1f 18758306
12. A Inoue K Kobayashi K Usui, et al. 2009 First-line gefitinib for patients with advanced non-small-cell lung cancer harboring epidermal growth factor receptor mutations without indication for chemotherapy J Clin Oncol 27 1394 1400 1:CAS:528:DC%2BD1MXksF2iu7c%3D 10.1200/JCO.2008.18.7658 19224850
13. Pas-Ares L, Sanchez JM, Garcia-Velasco A et al. (2006) Prospective phase II trial of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 24 (Suppl): 369s, abstr 7020
14. Mok T, Wu Yi-L, Thongprasert S et al. (2008) Phase III randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced NSCLC (I-PASS). Ann Oncol 19 (Suppl 8): viii1, abstr LBA2
15. T Mitsudomi T Kosaka H Endoh, et al. 2005 Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence J Clin Oncol 23 2513 2520 1:CAS:528:DC%2BD2MXjvVyktLs%3D 10.1200/JCO.2005.00.992 15738541 (Pubitemid 47050841)
16. W Pao V Miller M Zakowski, et al. 2004 EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci U S A 101 13306 13311 1:CAS:528:DC%2BD2cXnvFems70%3D 10.1073/pnas.0405220101 15329413 (Pubitemid 39209661)
17. A Inoue T Suzuki T Fukuhara, et al. 2006 Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations J Clin Oncol 24 3340 3346 1:CAS:528:DC%2BD28Xot1Kis7g%3D 10.1200/JCO.2005.05.4692 16785471 (Pubitemid 46638887)
18. DH Lee JY Han HG Lee, et al. 2005 Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers Clin Cancer Res 11 3032 3037 1:CAS:528:DC%2BD2MXjtlejtLc%3D 10.1158/1078-0432.CCR-04-2149 15837758 (Pubitemid 40525209)
19. F Cappuzzo C Gigorio PA Janne, et al. 2007 Prospective study of gefitinib in epidermal growth factor receptor fluorescence in situ hybridization- positive/phospho-Akt-positive or never smoker patients with advanced non-small-cell lung cancer: the ONCOBELL trial J Clin Oncol 25 2248 2255 1:CAS:528:DC%2BD2sXnsVShur0%3D 10.1200/JCO.2006.09.4300 17538169 (Pubitemid 46954651)